Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

naturewill
China
Product Name: Vinpocetine
Price: ￥Inquiry/5mg ￥Inquiry/20mg ￥Inquiry/100mg ￥Inquiry/1g
Purity: 98.0%
Stocking Period: Inquiry
Contact: Bella
Email: 3157321941@qq.com

Henan Tianfu Chemical Co., Ltd.
China
Product Name: Vinpocetine
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson
Email: info@tianfuchem.com

42971-09-5

42971-09-5 structure

42971-09-5 structure

Name: Vinpocetine
Chemical Name: Vinpocetine
CAS Number: 42971-09-5
Molecular Formula: C₂₂H₂₆N₂O₂
Molecular Weight: 350.454
Catalog: API Circulatory system medication Peripheral vasodilator
Create Date: 2018-04-04 08:00:00
Modify Date: 2026-06-30 08:46:36
Vinpocetine(Cavinton; Ethyl apovincaminate) is a selective for PDE1 (IC50 = 21 μM). Also blocks voltage-gated Na+ channels.IC50 value:Target: PDE1; Na+ channel

Name	Vinpocetine
Synonyms	VINPOCETIN (3α, 16α)-eburnamenine-14-cboxylic acid ethyl ester Ethyl (+)-cis-apovincaminate Eburnamenine-14-cboxylic acid ethyl ester, (3α, 16α)-Eburnamenine-14-cboxylic acid ethyl ester 3a,16a-Eburnamenine-14-cboxylic Acid Ethyl Ester, 3a,16a-Apovincaminic Acid Ethyl Ester, Ethyl Apovincamin-22-oate, RGH-4405, Cavinton 3-alpha,16-alpha-Apovincaminic acid ethyl ester Eburnamenine-14-cboxylic acid, ethyl ester, (3α,16α) (+)-Apovincaminic acid ethyl ester Vinpoeetine Eburnamenine-14-cboxylic acid, ethyl ester, (3a,16a)- (9CI) ethylester,(3-alpha,16-alpha)-eburnamenine-14-cboxylicaci Ethyl (3alpha,16alpha)-eburnamenine-14-cboxylate C22H27N2O2 cis-Apovincaminic acid ethyl ester VINPOCETINE, MM(CRM STANDD) Vinpocetine CRS Eburnamenine-14-cboxylic acid, ethyl ester, (3a,16a) apovincaminated’ethyle Vinpocetine, >= (3α,16α)-Eburnamenine (3α,16α)-Eburnamenine-14-cboxylic acid ethyl Voacanga Africana Extract Vinpocetine RGH-4405 Tcv-3B (3α,16α)-Eburnamenine-14-carboxylic acid ethyl ester EBURNAMENINE ethylapovincaminate Ultra-Vinca Ceratin：RGH-4405 AY-27255 Apovincaminic acid ethyl ester Vinpocetinum (3α,16α) Vinpocetine //BP Eburnamenine-14-cboxylic acid, ethyl ester, (3alpha,16alpha) Eburnamenine-14-carboxylic acid ethyl ester (+)-cis-Apovincaminic acid ethyl ester High quality Vinpocetine BP VINPOCETINE(RG) Ceractin Ethyl apovincaminate vinpocetine (3alpha,16alpha)-Eburnamenine-14-cboxylic acid ethyl ester ethyl eburnamenine-14-cboxylate VINPOCETINE EINECS 256-028-0 (41S,13aS)-ethyl 13a-ethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-cboxylate (3A,16A)-EBURNAMENINE-14-CBOXYLIC ACID ETHYL ESTER MFCD00211233 EBURNAMENINE-14-CBOXYLIC ACID ETHYL ESTER Vinpocetine (RGH-4405 Ethyl(13aS,13bS)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-cboxylate ETHYL APOVINCAMIN-22-OATE (3α，16α)-Eburnamemne-14-cboxylic acid ethyl ester CAVINTON 3-alpha,16-alpha-apovincaminicacidethylester Vinpocetine a selective inhibitor for PDE1 3A,16A-APOVINCAMINIC ACID ETHYL ESTER

Description	Vinpocetine(Cavinton; Ethyl apovincaminate) is a selective for PDE1 (IC50 = 21 μM). Also blocks voltage-gated Na+ channels.IC50 value:Target: PDE1; Na+ channel
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Cardiovascular Disease Research Areas >> Neurological Disease
References	[1]. Patyar S, et al. Role of vinpocetine in cerebrovascular diseases.Pharmacol Rep. 2011;63(3):618-28. [2]. Vaizova OE, et al. Endothelium-protective effects of vinpocetine, pentoxifylline and enalapril in patients with chronic brain ischemia.Eksp Klin Farmakol. 2011;74(4):10-3. [3]. El-Laithy HM, et al. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies.Eur J Pharm Biopharm. 2011 Jan;77(1):43-55. [4]. Alexandre E. Medina Vinpocetine as a potent antiinflammatory agent PNAS June 1, 2010 vol. 107 no. 22 9921-9922 [5]. Kye-Im Jeon et al. Vinpocetine inhibits NF-κB-dependent inflammation via an IKK-dependent but PDE-independent mechanism PNAS May 25, 2010 vol. 107 no. 21 9795-9800

Density	1.3±0.1 g/cm3
Boiling Point	419.5±45.0 °C at 760 mmHg
Melting Point	147-153ºC dec
Molecular Formula	C₂₂H₂₆N₂O₂
Molecular Weight	350.454
Flash Point	207.5±28.7 °C
Exact Mass	350.199432
PSA	34.47000
LogP	5.14
Vapour Pressure	0.0±1.0 mmHg at 25°C
Index of Refraction	1.666

CHEMICAL IDENTIFICATION

RTECS NUMBER :: JW4792000

CHEMICAL NAME :: Eburnamenine-14-carboxylic acid, ethyl ester, (3-alpha,16-alpha)-

CAS REGISTRY NUMBER :: 42971-09-5

LAST UPDATED :: 199806

DATA ITEMS CITED :: 14

MOLECULAR FORMULA :: C22-H26-N2-O2

MOLECULAR WEIGHT :: 350.50

WISWESSER LINE NOTATION :: T D6 B5666 2AB S CN MN&&TTTJ Q2 SVO2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 503 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1938,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 119 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 35,1919,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 32 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 35,1919,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 534 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1938,1976

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 117 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 35,1919,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 45 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 35,1919,1984 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4375 mg/kg/5W-I

TOXIC EFFECTS :: Behavioral - fluid intake Kidney, Ureter, Bladder - urine volume increased Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 10,1847,1982

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 14560 mg/kg/26W-I

TOXIC EFFECTS :: Liver - changes in liver weight Kidney, Ureter, Bladder - urine volume increased Endocrine - changes in adrenal weight

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 10,1847,1982 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 100 mg/kg

SEX/DURATION :: female 14-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1938,1976

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 450 mg/kg

SEX/DURATION :: female 7-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1938,1976

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1 gm/kg

SEX/DURATION :: female 7-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 11,1125,1983

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1 gm/kg

SEX/DURATION :: female 7-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 11,1125,1983

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 65 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - abortion

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 11,3585,1983

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1750 mg/kg

SEX/DURATION :: female 14 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 11,3585,1983

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Precautionary Statements	P301 + P312 + P330
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xn:Harmful
Risk Phrases	R22
Safety Phrases	S36
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	JW4792000
HS Code	2933990090

Precursor 9
64-17-5 4880-92-6 40163-56-2 141-52-6
23944-42-5 82398-60-5 1617-90-9 77793-33-0
85647-38-7
DownStream 0

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.